PFE (Pfizer) How high will it go? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go?

PFE 25.74

+0.9%

12:04 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Brian Malloy who wrote (7868)	6/10/1999 11:34:00 AM
From: Anthony Wong	Read Replies (3) of 9523

Analysts ratings issued on PFE today: maintained ''hold'' by analyst James A. Kelly at Credit Suisse First Boston Inc. reiterated ''neutral'' by analyst Jami Rubin at Morgan Stanley Dean Witter. downgraded to ''neutral'' from ''buy'' by analyst Christina Heuer at Salomon Smith Barney. The 12-month target price is $105.00 per share. The price target was cut to $105 from $150 per share. maintained ''hold'' by analyst James E. Flynn at ING Baring Furman Selz LLC. maintained ''buy'' by analyst Jeffrey Chaffkin at PaineWebber Inc. The 12-month target price is $143.00 per share. maintained ''neutral'' by analyst C. Anthony Butler at Lehman Brothers. The 12-month target price is $130.00 per share. maintained ''hold'' by analyst Mara Goldstein at CIBC World Markets Inc.. maintained ''buy'' by analyst Jerome R. Brimeyer at Warburg Dillon Read Inc.. The 12-month target price is $140.00 per share. maintained ''attractive'' by analyst Patricia L. Bank at Vector Securities International. maintained ''strong buy'' by analyst Stephen Scala at SG Cowen. The 12 to 18-month target price is $ 125 per share. downgraded to ''hold'' from ''buy'' by analyst Leonard S. Yaffe Md at Banc of America Securities. maintained short-term ''neutral'' by analyst Michael Krensavage at Brown Brothers Harriman & Co. The long-term rating is also ''neutral.'' From Bloomberg: quote.bloomberg.com Lehman Brothers said Thursday that analyst Anthony Butler cut his earnings estimate for Pfizer Inc. for 1999 to $2.44 a share from $2.46. -- cut his estimate for 2000 to $2.92 from $2.95. -- lowered sales estimates for the Pfizer antibiotic Trovan for 1999 to $190 million from $370 million. -- lowered sales estimates for Trovan for 2000 to $325 million from $600 million. -- Pfizer said Wednesday it would tell doctors to limit the use of Trovan because of reports indicating it may harm the liver. biz.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next